New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2013
10:00 EDTAWK, KWK, UNFI, SCTY, AGN, MCY, VITC, SD, GRP, FMS, DGI, DDAIF, DVA, BIG, CWHOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Water (AWK) downgraded to Neutral from Buy at Citigroup... Big Lots (BIG) downgraded to Hold from Buy at Canaccord... DaVita (DVA) downgraded to Hold from Buy at Deutsche Bank... Daimler AG (DDAIF) downgraded to Neutral from Buy at Citigroup... DigitalGlobe (DGI) downgraded to Hold from Buy at Benchmark Co... Fresenius Medical (FMS) downgraded to Sector Perform from Outperform at RBC Capital... Granite Real Estate (GRP) downgraded to Sector Perform from Outperform at RBC Capital... Lincoln Educational (LINC) downgraded to Underperform from Market Perform at BMO Capital... SandRidge Energy (SD) downgraded to Underperform from Market Perform at BMO Capital... Vitacost.com (VITC) downgraded to Sell from Neutral at Roth Capital... Mercury General (MCY) downgraded to Neutral from Outperform at Macquarie... Allergan (AGN) downgraded to Neutral from Buy at Buckingham... SolarCity (SCTY) downgraded to Hold from Buy at Needham... United Natural Foods (UNFI) downgraded to Hold from Buy at Argus... Quicksilver Resources (KWK) downgraded to Hold from Buy at MLV Equity... CommonWealth REIT (CWH) downgraded to Sell from Hold at Stifel Nicolaus.
News For AWK;BIG;DVA;DDAIF;DGI;FMS;GRP;SD;VITC;MCY;AGN;SCTY;UNFI;KWK;CWH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 15, 2014
13:07 EDTAGNAllergan seeing arb-related selling pressure, says BMO Capital
Subscribe for More Information
11:02 EDTDVAWashington Trust provides $4.84M in financing for Connecticut building
Washington Trust's Commercial Real Estate Group recently provided $4.84M to Newtown Medical Office I to finance the construction of a two-story suburban medical office building in Newtown, Connecticut. The building will feature 25,806 square-feet of rentable space. More than 9,400 square-feet of the building is leased to national dialysis treatment providers, DaVita, a division of DaVita HealthCare Partners (DVA). The Washington Trust Company is a subsidiary of Washington Trust Bancorp (WASH).
10:02 EDTDDAIFOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:36 EDTSDSandRidge Energy downgraded to Underperform from Neutral at Credit Suisse
Subscribe for More Information
08:23 EDTSCTYSolarCity offers Solar Bonds to investors
Subscribe for More Information
08:07 EDTSCTYSolarCity files automatic mixed securities shelf
Subscribe for More Information
07:32 EDTAWKRedChip Companies to hold a virtual conference
Subscribe for More Information
06:40 EDTUNFIUnited Natural Foods upgraded to Overweight at Piper Jaffray
Subscribe for More Information
06:04 EDTSDStocks with implied volatility above IV index mean; PWE SD
Subscribe for More Information
05:48 EDTUNFIUnited Natural Foods upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray upgraded United Natural Foods to Overweight with a $74 price target.
05:30 EDTDDAIFDaimler AG upgraded to Overweight from Underweight at Barclays
October 14, 2014
06:03 EDTAGNMarket overreacted to new Irish tax rules, says BMO Capital
BMO Capital believes the market may have overreacted yesterday to the report that Ireland is eliminating the "Double Irish" tax loophole. The firm says Allergan (AGN) confirmed that it incorporated potential changes to Irish tax law in its recently raised earnings guidance while Mallinckrodt (MNK) said it does expect the new tax structure to have an immediate impact. BMO views yesterday's pullback in shares of Allergan, Mallinckrodt and Actavis (ACT) as an overreaction.
05:58 EDTSDStocks with implied volatility above IV index mean; HTZ SD
Subscribe for More Information
05:56 EDTDDAIFDaimler sees FY14 industrial free cash flow significantly lower than last year
Daimler is reviewing its guidance for the free cash flow of its industrial business excluding the effects of acquisitions and disposals for FY14. Hitherto, Daimler had assumed that the free cash flow of the industrial business adjusted for the effects of acquisitions and disposals would probably be significantly lower in 2014 than in the previous year. The individual divisions continue to aim for the following EBIT from the ongoing business in FY14: Mercedes-Benz Cars: significantly above the prior-year level, Daimler Trucks: significantly above the prior-year level, Mercedes-Benz Vans: at the prior-year level, Daimler Buses: significantly above the prior-year level, and Daimler Financial Services: slightly above the prior-year level.
05:55 EDTDDAIFDaimler reports Q3 industrial free cash flow ex-items EUR 2.9B
Subscribe for More Information
October 13, 2014
10:58 EDTSCTYSolarCity volatility elevated on wide price movement
Subscribe for More Information
10:08 EDTDGIOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:03 EDTSCTYSolarCity lowered pricing in California, says JPMorgan
JPMorgan says SolarCity lowered its pricing in California, implementing a fixed price of 15c per watt, down from a prior average of 17c. To reflect the change, SolarCity dropped the NPV of its average new residential deployment to $1.75 per watt from $2.19 historically, the firm notes. JPMorgan cut its Retained Value estimates and dropped its price target for SolarCity shares to $74 from $83. The firm believes the price change could be tied to the proposed compression of rate tiers in 2015, allowing the company to address a larger market. It keeps an Overweight rating on SolarCity.
07:43 EDTDGIDigitalGlobe initiated with an Overweight at Morgan Stanley
Subscribe for More Information
06:39 EDTAGNAllergan takeout value at or above $210 per share, says Leerink
Leerink believes Allergan's takeover value is now at or above $210 per share given the company's recent execution. After speaking with management, the firm says Allergan's upside in Q3 was driving by fundamentals, not cost cuts. It continues to view the "most likely and straightforward outcome" for Allergan as being an outright sale of the company. Leerink raised its price target for shares to $215 from $184 and keeps an Outperform rating on Allergan.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use